MucormycosisNCT05212961
COVID-19 and Rhino-orbital Mucormycosis
An observational study of Mucormycosis, run by Minia University at 1 site in Egypt.
Trial summary
Detect the clinical presentation and outcome of post covid-19 fungal mucormycosis in patients referred to Minia university Hospital. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Mucormycosis
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 28 Dec 2021to 28 Sep 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients who had fungal rhino-orbital infection and positive PCR test for Covid-19. was confirmed.
Who may be able to join
- Patients who had positive PCR test for Covid-19.
- Fungal rhino-orbital infection was confirmed.
Who cannot join
- Suspected patient with COVID-19 not confirmed with PCR
- Incomplete data
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Clinical Profile and Outcome of Post Covid-19 Rhino-orbital Fungal Mucormycosis in Minia Governorate
Detect the clinical presentation and outcome of post covid-19 fungal mucormycosis in patients referred to Minia university Hospital.
- Conditions
- Mucormycosis
- Medical subject headings
- Mucormycosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Outcome of rhino-orbital mucormycosis in COVID-19 patients
Data of the patients who had post Covid-19 fungal mucormycosis in the last year will be revised to detect clinical presentation and final outcome
Measured: 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2022
- Study start28 Dec 2021
- Primary completion28 Jun 2023
- Study completion28 Sep 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MucormycosisStudies of the same condition, open and under way.
- More trials run by Minia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Minia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sahar T A Abdelaziz, Minia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05212961
- Sponsor's protocol ID
- Ophthalmology
- Status last verified
- Oct 2023
- First submitted
- 24 Jan 2022
- Last updated
- 18 Oct 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Profile and Outcome of Post Covid-19 Rhino-orbital Fungal Mucormycosis in Minia Governorate
- ClinicalTrials.gov ID
- NCT05212961
- Acronym / sponsor ID
- Ophthalmology
- Conditions
- Mucormycosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Minia UniversityUniversity, hospital or other
- Study start
- 28 Dec 2021 (actual)
- Primary completion
- 28 Jun 2023 (actual)
- Study completion
- 28 Sep 2023 (actual)
- First posted
- 28 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Detect the clinical presentation and outcome of post covid-19 fungal mucormycosis in patients referred to Minia university Hospital.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients who had fungal rhino-orbital infection and positive PCR test for Covid-19. was confirmed.
Key inclusion criteria (2 listed)
- Patients who had positive PCR test for Covid-19.
- Fungal rhino-orbital infection was confirmed.
Key exclusion criteria (2 listed)
- Suspected patient with COVID-19 not confirmed with PCR
- Incomplete data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Outcome of rhino-orbital mucormycosis in COVID-19 patients
Time frame: 9 months
Data of the patients who had post Covid-19 fungal mucormycosis in the last year will be revised to detect clinical presentation and final outcome
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Oct 2023.
Related trials for Mucormycosis
RecruitingPhase 1
Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections
Aspergillos, Mucormye
RecruitingObservational study
Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
Mucormycosis
Recruiting
Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.
Hemifacial Microsomia, Mucormycosis
RecruitingObservational study
Biomarkers for Invasive Mucormycosis
Mucorales Infection, Mucormycosis
RecruitingObservational study
Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value
Pulmonary Mucormycosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Mucormycosis, run by Minia University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Outcome of rhino-orbital mucormycosis in COVID-19 patients (time frame: 9 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2023.